Bangwei Cao

Title: Bangwei Cao: Innovator in Tumor Treatment

Introduction

Bangwei Cao is a prominent inventor based in Beijing, China. He has made significant contributions to the field of oncology, particularly in the development of treatments for tumors that are unresponsive to immune checkpoint inhibitors.

Latest Patents

Cao holds a patent for the use of baicalin in the preparation of a drug aimed at treating tumors that are resistant to immune checkpoint inhibitors (ICIs) and undergoing hyperprogression. This innovative approach targets excessive Foxp3Treg cells, which contribute to the tumor's non-responsiveness. The patent outlines the use of baicalin in combination with ICIs to effectively inhibit these cells, thereby enhancing the anti-tumor sensitization effect. The targeted tumors include melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), liver cancer, colorectal cancer (CRC), urothelial bladder cancer, and pancreatic cancer.

Career Highlights

Bangwei Cao is affiliated with Beijing Friendship Hospital, Capital Medical University, where he continues to advance his research and clinical applications. His work has garnered attention for its potential to improve treatment outcomes for patients with challenging tumor types.

Collaborations

Cao collaborates with notable colleagues, including Dan Yan and Yu Zhang, who contribute to his research efforts and innovations in the field of cancer treatment.

Conclusion

Bangwei Cao's innovative work in the use of baicalin for treating tumors unresponsive to ICIs represents a significant advancement in oncology. His contributions are paving the way for more effective cancer therapies, ultimately benefiting patients worldwide.